Last reviewed · How we verify
Cream Base
Cream Base, marketed by Ahmed A. H. Abdellatif, holds a position in the dermatological segment with a key composition patent expiring in 2028. The drug's market position is bolstered by its current marketing status, providing a stable revenue stream. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Cream Base |
|---|---|
| Also known as | Aging group recieving placebo dosage form |
| Sponsor | Ahmed A. H. Abdellatif |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of MI Paste Plus™ on Streptococcus Mutans and White Spot Lesions in Fixed Orthodontics (NA)
- M-PART in Head and Neck Cancer Patients Treated With KeraStat Cream for Acute Radiation Dermatitis (NA)
- Effect of Cream Paste Containg Pleuran on Selected Skin Dermatoses (Neonatal Pustulosis, Diaper Dermatitis, Perioral Dermatitis). (NA)
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (PHASE3)
- An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa (PHASE3)
- Comparative Effects of Scooping Mobilization and Dynamic Cupping Therapy on Elbow Stiffness (NA)
- An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia (PHASE3)
- Next Generation Personalized Neuroblastoma Therapy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cream Base CI brief — competitive landscape report
- Cream Base updates RSS · CI watch RSS
- Ahmed A. H. Abdellatif portfolio CI